Patents by Inventor Nilabh Shastri

Nilabh Shastri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnosis of prostate cancer with SPAS-1 cancer antigen
    Patent number: 7704701
    Abstract: Compounds and methods for inducing protective immunity against cancer are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more SPAS-1 proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and pharmaceutical compositions for immunization against cancer, or can be used for the diagnosis of cancer and the monitoring of cancer progression.
    Type: Grant
    Filed: January 29, 2007
    Date of Patent: April 27, 2010
    Assignee: The Regents of the University of California
    Inventors: James P. Allison, Marcella Fasso, Nilabh Shastri
  • SPAS-1 cancer antigen
    Publication number: 20070202121
    Abstract: Compounds and methods for inducing protective immunity against cancer are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more SPAS-1 proteins and DNA molecules encoding such polypeptides.
    Type: Application
    Filed: January 29, 2007
    Publication date: August 30, 2007
    Inventors: James Allison, Marcella Fasso, Nilabh Shastri
  • ERAAP modulators regulate immune responses
    Patent number: 7232570
    Abstract: An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an effective amount of an inhibitor of ERAAP activity; confirming a resultant inhibition of said ERAAP activity and confirming a resultant immune response modulation in the patient. A variety of selective inhibitors are shown to be effective, including amino thiols, such as leucine thiol, ERAAP-specific antibody complementarity-determining region, and an ERAAP-specific siRNA.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: June 19, 2007
    Assignee: Regents of the University of California
    Inventors: Nilabh Shastri, Thomas Serwold
  • ERAAP modulators regulate immune responses
    Publication number: 20060099217
    Abstract: An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an effective amount of an inhibitor of ERAAP activity; confirming a resultant inhibition of said ERAAP activity and confirming a resultant immune response modulation in the patient. A variety of selective inhibitors are shown to be effective, including amino thiols, such as leucine thiol, ERAAP-specific antibody complementarity-determining region, and an ERAAP-specific siRNA.
    Type: Application
    Filed: December 13, 2005
    Publication date: May 11, 2006
    Inventors: Nilabh Shastri, Thomas Serwold
  • ERAAP modulators regulate immune responses
    Patent number: 7005269
    Abstract: An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an effective amount of an inhibitor of ERAAP activity; confirming a resultant inhibition of said ERAAP activity and confirming a resultant immune response modulation in the patient. A variety of selective inhibitors are shown to be effective, including amino thiols, such as leucine thiol, ERAAP-specific antibody complementarity-determining region, and an ERAAP-specific siRNA.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: February 28, 2006
    Assignee: The Regents of the University of California
    Inventors: Nilabh Shastri, Thomas Serwold
  • ERAAP modulators regulate immune responses
    Publication number: 20030228314
    Abstract: An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an effective amount of an inhibitor of ERAAP activity; confirming a resultant inhibition of said ERAAP activity and confirming a resultant immune response modulation in the patient. A variety of selective inhibitors are shown to be effective, including amino thiols, such as leucine thiol, ERAAP-specific antibody complementarity-determining region, and an ERAAP-specific siRNA.
    Type: Application
    Filed: June 6, 2002
    Publication date: December 11, 2003
    Applicant: The Regents of the University of California
    Inventors: Nilabh Shastri, Thomas Serwold
  • SPAS-1 cancer antigen
    Publication number: 20020150588
    Abstract: Compounds and methods for inducing protective immunity against cancer are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more SPAS-1 proteins and DNA molecules encoding such polypeptides.
    Type: Application
    Filed: September 13, 2001
    Publication date: October 17, 2002
    Inventors: James P. Allison, Marcella Fasso, Nilabh Shastri